GlassScriptPhysician profile
David S Michelson
NPI 1013063437
$2,618.16
in general payments reported to CMS, 2019-2025
19 companies · $42.38 in 2025
The $42.38 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.14 · 2020: $321 · 2021: $650 · 2022: $549 · 2023: $497 · 2024: $463 · 2025: $42.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $862.40 | 2019-2022 | |
| Abbvie INC. | $634.09 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $163.51 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $135.64 | 2022-2024 | Tyrvaya, Ryzumvi |
| Rxsight INC | $119.21 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Horizon Therapeutics Plc | $116.02 | 2021-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $91.77 | 2020-2023 | |
| Thea Pharma INC. | $74.71 | 2022-2024 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $62.47 | 2021-2023 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $62.12 | 2021-2023 | Meibomian Gland Evaluator, Lipiflow System Activator (Disposable) |
| Sight Sciences, INC. | $53.34 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $50.56 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $47.74 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $35.82 | 2019-2023 | Cequa |
| Alcon Vision LLC | $26.04 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.07 | 2021 | |
| Shire North American Group INC | $20.63 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Aerie Pharmaceuticals, INC. | $18.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Michelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.